Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00387283
Other study ID # AVI-4020-21b
Secondary ID
Status Completed
Phase Phase 1
First received October 11, 2006
Last updated July 6, 2009
Start date October 2006
Est. completion date June 2009

Study information

Verified date July 2009
Source Sarepta Therapeutics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier. This study will assess the amount of drug that goes across the blood-brain barrier and the drug levels measured in both the blood and urine.

The objective of this study is to find out how much and how fast this drug crosses this barrier.


Description:

AVI-4020 was designed to interfere with West Nile virus translation, and has been shown to cross the blood-brain barrier in both normal and inflamed meninges in a clinical study in patients with severe West Nile virus disease.

At issue, is whether this observation is limited to AVI-4020 PMO drug, or is observed with other PMO drugs. This study is one of three to assess the specific ability of PMO drugs to cross the blood-brain barrier, using similar dosing, and PK assessment time points. In order to rigorously assess the pharmacokinetics, this study is being performed in healthy volunteers at a single point in time.

The ability of other PMO drugs to cross the blood-brain barrier will set the stage for future studies that exploit this product characteristic.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date June 2009
Est. primary completion date December 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- Adult males 18 years to 64 years of age;

- Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range)

- Signed and dated written informed consent form; and

- Willing to participate in all study activities and all requirements, including effective contraception (viz., a double-barrier method) during the 7-day study surveillance period.

Exclusion Criteria:

- Hematology, serum chemistry (exclusive of electrolytes), and urinalysis laboratory test values >2 times upper limits of normal or anemia (hemoglobulin <11 g/dL), leukopenia (total white blood count <3,000/µL or total neutrophils <1,500/ µL) or thrombocytopenia (platelets <100,000/µL). Electrolytes and coagulation values exceeding normal ranges are to be excluded.

- Body Mass Index (BMI) >35.

- Calculated creatinine clearance (by the Cockroft and Gault Formula) <70 mL/min, based on age and gender.

- Positive HIV-1 or HIV-2 serology.

- Positive HCV serology and/or positive plasma HCV-RNA status.

- Positive Hepatitis B status.

- Solid or hematopoetic organ transplant recipient.

- Active illness or recent illness within 30 days of the first dose of study drug.

- History of any of the following: brain injury, neoplasm, chronic or migraine headaches, cancer, meningitis or hydrocephalus.

- Usage of any prescribed, over-the-counter or illicit drug(s) within 30 days of study drug administration. Use of herbal remedies and/or supplements at the discretion of the Investigator.

- Unwilling to practice effective contraception during the study period.

- Participation in any clinical interventional trial within the previous 6 months.

- Positive drug urine screen.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
AVI-4020 Injection


Locations

Country Name City State
United States NW Kinetics Tacoma Washington

Sponsors (1)

Lead Sponsor Collaborator
Sarepta Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine if the study drug penetrates the blood brain barrier following a single dose of AVI-4020, and if it does, the associated CSF, plasma and urine pharmacokinetics
Secondary Safety, Tolerability
See also
  Status Clinical Trial Phase
Completed NCT00069316 - Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease Phase 2
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00068055 - IVIG - West Nile Encephalitis: Safety and Efficacy Phase 1/Phase 2
Completed NCT00138463 - West Nile Virus Natural History N/A
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Withdrawn NCT04371003 - Prospective Investigation of Oxidative Stress in West Nile Virus Infection
Completed NCT05294003 - West Nile Virus Seroprevalence Under Bird Ringers
Completed NCT02186626 - Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age Phase 1
Completed NCT00515385 - A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults Phase 1